Murwere wekutanga akatorwa mamota akasimba

Jubilant Therapeutics Inc nhasi yakazivisa kutorwa kwemurwere wekutanga muChikamu I/II chekiriniki yeJBI-802 muvarwere vane mapundu akasimba. JBI-802 ndeyekutanga-mu-kirasi, diki-morekuru, inopihwa nemuromo dual inhibitor yeLSD1 uye HDAC6 iyo yakaratidza synergistic anti-tumor chiitiko mumhando dzemhuka.  

Muyedzo wePhase I/II chinyorwa chakavhurika, chezvikamu zviviri zvedosi kukwira uye chidzidzo chekuwedzera chakagadzirirwa kutsanangura kuchengetedzeka uye kushivirira, kuongorora kufungidzira biomarkers uye kuongorora kwekutanga chiitiko cheJBI-802 mune vanopfuura zana vatori vechikamu muzvidzidzo vane mabundu akasimba akasimba. Mamwe mashoko pamusoro pekuedzwa kwekliniki anogona kuwanikwa paNCT100.

Hari S Bhartia, Sachigaro, Jubilant Therapeutics Inc. vakagovera pachiziviso ichi, “Takabva kure kubva mukuwanikwa kwezvinodhaka kusvika pakutorwa kwekutanga-mu-munhu. Tinotarisira kuita shanduko muhupenyu hwevarwere. Hunyanzvi hwedu mukugadzira dhizaini dhizaini uye makemikari emushonga zvinoita kuti tikwanise kugadzira akapatsanurwa chaiwo ekurapa ane zvinhu zvitsva chaizvo.

Syed Kazmi, Chief Executive Officer, Jubilant Therapeutics Inc. akati, "JBI-802, inogadzirisa zvibodzwa zviviri zvakasimbiswa zveoncology zvine hukama hwakafanana uye nekukurumidza on / off exposure kinetics, zvichitungamira kune synergistic anti-bundu chiitiko nenjodzi yakadzikira yethrombocytopenia. Iyi ndiyo yedu yekutanga yemukati yakagadzirwa chigadzirwa mumiriri wekupinda mukiriniki yekuvandudza. Zvimwe zvirongwa zvekufambira mberi zvinosanganisira oral brain penetrant inhibitor yePRMT5, JBI 778, uye yemuromo uropi inopinda PDL1 inhibitor, JBI 2174, yegomarara retsinga pakati pevamwe.